Meditech and biotech contract research organization Boston Biomedical Associates (BBA) has merged with Factory-CRO Group, a medtech and in vitro diagnostics contract research firm based in Bilthoven, Netherlands.
The merger allows Factory-CRO Group, which already had a U.S. presence, to expand its services in this country. The company said it is the only medical device and medical technology CRO that offers services in the U.S., Europe, Australia and New Zealand.
The merger with Marlborough, Mass.-based Boston Biomedical is the latest transaction for Factory CRO, which acquired Five Corners (Artarmon, Australia) in June 2018 MileStone Research Organization (San Diego, Calif.) in 2017.
“BBA is excited to join Factory-CRO’s worldwide group as it will allow us to expand our comprehensive service offering to our clients,” said Lauren Baker, president and CEO of BBA, in a prepared statement. “The alignment of Factory-CRO and BBA’s core values and approach to engagements combined with our collective therapeutic competencies ensures that our clients now have improved access to our global clinical trial execution resources, and our regulatory and medical expertise.”
Factory CRO’s clients had consistently asked the company to expand its North American services, according to CEO Dirk Meijer, M.D. “BBA’s ability to provide CRO/Consultative service in North America was a missing link in our global offerings,” Meijer said.
Factory-CRO Group is a full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics and device-drug combination products internationally. It offers trial management services in orthopedics, cardiovascular health, dermatology and aesthetics. Boston Biomedical offers clinical trial execution services across a broad range of therapeutic areas, including orthopedic, cardiovascular, endocrine and neurologic disorders.